Management of multidrug-resistant enterococcal infections

Slides:

Advertisements

Similar presentations

Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages

Advertisements

Laboratory diagnosis and biosafety issues of biological warfare agents

Gut bacterial microbiota and obesity

Salvage therapy for multidrug-resistant tuberculosis

Approach to diagnosis of infective endocarditis

D. Khalil, M. Hultin, M.U. Rashid, B. Lund

P. Clarke, S. Murchan, E.G. Smyth, H. Humphreys

The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram- positive bacteria M.J. Rybak Clinical Microbiology and Infection

Evolution of extended-spectrum β-lactamases by mutation

Increased conjugation frequencies in clinical Enterococcus faecium strains harbouring the enterococcal surface protein gene esp B. Lund, H. Billström,

A.K. Reddy, P. Garg, I. Kaur Clinical Microbiology and Infection

Ecological replacement of Enterococcus faecalis by multiresistant clonal complex 17 Enterococcus faecium J. Top, R. Willems, H. Blok, M. de Regt, K.

Gentamicin susceptibility in Escherichia coli related to the genetic background: problems with breakpoints L. Jakobsen, D. Sandvang, V.F. Jensen, A.M.

Ecological replacement of Enterococcus faecalis by multiresistant clonal complex 17 Enterococcus faecium J. Top, R. Willems, H. Blok, M. de Regt, K.

Antimicrobial susceptibility of Streptococcus pneumoniae in Latin America: results from five years of the SENTRY Antimicrobial Surveillance Program M.

Genome-based insights into the evolution of enterococci

Is the prevalence of antibiotic-resistant organisms changing in Canadian hospitals? Comparison of point-prevalence survey results in 2010 and 2012 V.

Should standardized susceptibility testing for microbial biofilms be introduced in clinical practice? T. Coenye, D. Goeres, F. Van Bambeke, T. Bjarnsholt

Potential risk factors for infection with Candida spp

AZD2563, a novel oxazolidinone: definition of antibacterial spectrum, assessment of bactericidal potential and the impact of miscellaneous factors on.

W. Witte, B. Pasemann, C. Cuny Clinical Microbiology and Infection

A multicentre analysis of epidemiology of the nosocomial bloodstream infections in Japanese university hospitals M. Nagao Clinical Microbiology and.

H. Adibhesami, M. Douraghi, M. Rahbar, A. Abdollahi

Tracking changes in the vraSR and graSR two component regulatory systems during the development and loss of vancomycin non-susceptibility in a clinical.

D.E. Low Clinical Microbiology and Infection

Vector control: a cornerstone in the malaria elimination campaign

Sofie Arens, Jan Verhaegen, Ludo Verbist

Human health risks associated with antimicrobial-resistant enterococci and Staphylococcus aureus on poultry meat V. Bortolaia, C. Espinosa-Gongora, L.

Changes in Escherichia coli resistance patterns during and after antibiotic therapy: a longitudinal study among outpatients in Germany E. Raum, S. Lietzau,

The use and therapeutic drug monitoring of teicoplanin in the UK

Low prevalence of methicillin-resistant Staphylococcus aureus with reduced susceptibility to glycopeptides in Belgian hospitals C. Nonhoff, O. Denis,

Laboratory diagnosis and biosafety issues of biological warfare agents

Effects of gentamicin monotherapy for the initial treatment of community-onset complicated non-obstructive acute pyelonephritis due to Enterobacteriaceae.

Salvage therapy for multidrug-resistant tuberculosis

Control of infections due to extended-spectrum β-lactamase-producing organisms in hospitals and the community R.E. Warren, G. Harvey, R. Carr, D. Ward,

Evaluation of vancomycin MIC creep in methicillin-resistant Staphylococcus aureus infections—a systematic review and meta-analysis R. Diaz, V. Afreixo,

Elements of design: the knowledge on which we build

Microbiological and epidemiological studies of Enterococcus faecium resistant to amoxycillin in a university hospital in eastern France M. Thouverez,

In vitro selection of antibiotic resistance in Pseudomonas aeruginosa

Four-year epidemiological study of extended-spectrum β-lactamase-producing Enterobacteriaceae in a French teaching hospital L. Gibold, F. Robin, R.-N.

Levofloxacin in the treatment of ventilator-associated pneumonia

Metagenomics and probiotics

M. Aires-de-Sousa Clinical Microbiology and Infection

MIC distribution and inoculum effect of LY333328: a study of vancomycin-susceptible and VanA-type and VanC-type enterococci obtained from intensive care.

J. Garau Clinical Microbiology and Infection

T.M. File Clinical Microbiology and Infection

Update on antifungal resistance in Aspergillus and Candida

Harmonised monitoring of antimicrobial resistance in Salmonella and Campylobacter isolates from food animals in the European Union S. Bronzwaer Clinical.

P.M. Hawkey Clinical Microbiology and Infection

Comparative bactericidal activities of daptomycin, glycopeptides, linezolid and tigecycline against blood isolates of Gram-positive bacteria in Taiwan

The dynamic relationship between antibiotic use and the incidence of vancomycin- resistant Enterococcus: time-series modelling of 7-year surveillance data.

Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci H.L. DuPont, Z.-D. Jiang Clinical Microbiology.

Current experience in treating invasive zygomycosis with posaconazole

C. Gagliotti, L. Nobilio, M.L. Moro

P. Kaltsas, S. Want, J. Cohen Clinical Microbiology and Infection

Clinical Microbiology and Infection

W. Eugene Sanders, Christine C. Sanders

The in vitro activity of moxifloxacin against Haemophilus influenzae and Moraxella catarrhalis explored using a pharmacodynamic model Alasdair P. MacGowan,

C. Novais, T.M. Coque, J.C. Sousa, L.V. Peixe

New oral cephalosporins in pediatric community-acquired infections

Risk-factors and predictors of mortality in patients colonised with vancomycin-resistant enterococci V. Sakka, S. Tsiodras, L. Galani, A. Antoniadou,

Susceptibility of multi-drug-resistant Pseudomonas aeruginosa in intensive care units: results from the European MYSTIC study group† H. Goossens Clinical.

J.L. Balcázar Clinical Microbiology and Infection

Test results: characterising the antimicrobial activity of daptomycin

G.C. Schito Clinical Microbiology and Infection

AZD2563, a novel oxazolidinone: definition of antibacterial spectrum, assessment of bactericidal potential and the impact of miscellaneous factors on.

Bactericidal activity and synergy studies of BAL9141, a novel pyrrolidinone-3- ylidenemethyl cephem, tested against streptococci, enterococci and methicillin-resistant.

Impact of antibiotic restrictions: the patient's perspective

Activity of linezolid against Gram-positive cocci isolated in French hospitals as determined by three in-vitro susceptibility testing methods C. Muller-Serieys,

The future of diagnostic bacteriology

Presentation transcript:

Management of multidrug-resistant enterococcal infections C.A. Arias Clinical Microbiology and Infection Volume 16, Issue 6, Pages 555-562 (June 2010) DOI: 10.1111/j.1469-0691.2010.03214.x Copyright © 2010 European Society of Clinical Infectious Diseases Terms and Conditions

FIG. 1 Suggested therapeutic alternatives in severe infections caused by vancomycin-resistant enterococcal infections. (1) In rare cases of β-lactamase-produciing isolates, ampicillin-sulbactam (12–24 g/day) is suggested. The use of a continuous infusion is recommended by some experts. (2) Gentamicin or streptomycin. (3) Consider doses of 8–12 mg/kg day. (4) Agents with potential activity include tigecycline [62,63], doxycycline with rifampin or a fluoroquinolone (if susceptible to each agent). (5) Doses to up to 30 g/day could be considered. (6) Quinupristin-dalfopristin or linezolid are listed in the American Heart Association recommendations for the treatment of vancomycin and ampicillin-resistant Enterococcus faecium. Linezolid has been used with success in a few cases of meningitis as a result of vancomycin-resistant enterococci [61,74]. (7) if imipenem MIC < 32 mg/L. HLR, high-level resistance; HD, high-dose. Clinical Microbiology and Infection 2010 16, 555-562DOI: (10.1111/j.1469-0691.2010.03214.x) Copyright © 2010 European Society of Clinical Infectious Diseases Terms and Conditions